Inhibrx (INBX)

• Market cap: $1.39B
• 1 day: -0.86%
• 5 days: 1%
• 1 month: -11.57%
• 3 months: 43.62%
• 6 months: 17.8%
• Year to date: 25.92%
• 1 year: 538.88%
• 5 years: 655.32%
• 10 years: 655.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 110